BREAST CANCER

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

An innovative AI model enhances breast cancer recurrence predictions, outperforming traditional methods and offering tailored treatment insights for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.

In a recent phase 2 trial, TQB2102 showed promising antitumor activity and safety as a neoadjuvant therapy for HER2-positive breast cancer.

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.

Expert explores innovative strategies for managing early stage breast cancer, focusing on minimal residual disease and potential treatment adjustments.

Early-stage breast cancer patients face challenges with ctDNA detection, highlighting the need for clinical trials to improve outcomes and reduce recurrence risks.

Explore the advancements in minimal residual disease (MRD) assays, comparing tumor-informed and tumor-agnostic methods for enhanced cancer detection and treatment strategies.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.

Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.

The FDA approves pertuzumab-dpzb as the first interchangeable biosimilar for HER2-positive breast cancer, enhancing treatment options and accessibility.